YAVNE, Israel, Nov. 5, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD ), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, announces the appointment of Roland Frösing M.D., Ph.D. as MediWound's European Medical Director in support of its planned advancement of the EscharEx ® program for the debridement of chronic wounds as well as its efforts to expand market access and reimbursement for NexoBrid ® .
For more than a decade, Dr. Frösing served as a surgeon at the Sahlgrenska Univeristy Hospital in Sweden and thereafter held leading positions in Medical Affairs at Pfizer and Fujisawa/Astellas. Before joining MediWound, Roland served as Global Medical Director and head of Market Access at Mölnlycke Health Care, one of the world's leading advance wound care companies, where he led the global medical development and market access activities worldwide.
"We are very pleased to welcome Dr. Frösing to the MediWound team as he brings a wealth of relevant experience in the chronic wound market that will be of significant value as we advance plans for our global EscharEx development program. In addition, Roland's considerable expertise having led pharmaco-economic and market access teams in wound care, make him ideally suited to enhance our efforts to secure reimbursement for NexoBrid across Europe and, thereafter, in the U.S. As a fellow surgeon, Dr. Frösing can work closely with burn and wound specialists to support our efforts to transform NexoBrid from a novel therapy to a new standard-of-care," stated Gal Cohen, President and Chief Executive Officer of MediWound.
About MediWound Ltd.
MediWound is a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, as well as chronic and other hard-to-heal wounds. MediWound's first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency and from the Israeli and Argentinean Ministries of Health for removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues. For more information, please visit www.mediwound.com .
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the US Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecast, commercial results, clinical trials and the regulatory authorizations. In some cases, you can identify forward-looking statements by terminology such as "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," "predict," "potential," or the negative of these terms or other similar expressions. Forward-looking statements are based on MediWound's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors. In particular, you should consider the risks discussed under the heading "Risk Factors" in our annual report on Form 20-F for the year ended December 31, 2014 and information contained in other documents filed with or furnished to the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. The forward-looking statements made herein speak only as of the date of this announcement and MediWound undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
| Contacts: |
| Sharon Malka |
| Chief Financial & Operations Officer |
| MediWound Ltd. |
| ir@mediwound.co.il |
| Anne Marie Fields |
| Senior Vice President |
| LHA |
| 212-838-3777 |
| afields@lhai.com |
